BioMarin Pharmaceutical Inc.

NASDAQ:BMRN

Biotechnology

Healthcare
$61.43 -0.18%

-$0.10 today

Market cap
$11.90B
Beta
0.24
P/E (TTM)
39.4
EPS (TTM)
$1.40
52W Low $49.26High $66.28

Volume 3.07M

Average 2.04M

BMRN Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

BioMarin Pharmaceutical Inc.NASDAQ: BMRN

Depreciation & Amortization · Q3 FY2026 · quarter ended Sep 2026

Depreciation & amortization growth accelerates

Q3 FY2026 depreciation & amortization of $244.4B rose 1321909.8% year over year, ahead of the +295495.6% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 250212.3% from the prior quarter. Over 3 fiscal years it compounded at -7.9% a year.

Context

  • Depreciation & amortization amounted to 2.5% of revenue in FY2025, down 0.9 pp from a year earlier.
  • Depreciation & amortization increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +1321909.8% holds above the trailing-twelve-month pace of +295495.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$244.4B+250212.3% QoQ
Last fiscal yearDec 2025
$79.56M-17.5% YoY
LTMSep 2026
$244.53B+295495.6% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1321909.8%——
1 year-17.5%——
3-year CAGR-7.9%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
79.56M USD
Year-over-year change
-17.5%
4-year CAGR
-7.4%

Depreciation & Amortization vs competitors

How BMRN compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +295495.6% is the highest of 11, against a peer median of +1.3%.
  • Depreciation & amortization amounts to 23.8% of revenue for BMRN, versus a peer median of 1.9%.
BMRN Competitors
Depreciation & Amortization for BMRN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026$244.53B USD+295495.6%-7.9%23.8%
VRTXVertex Pharmaceuticals IncorporatedLTM Jun 2026$222.1M USD+11.2%+12.3%1.8%
PTCTPTC Therapeutics, Inc.LTM Jun 2026$55.3M USD+97.1%-33.0%5.5%
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 2026$54.76M USD-3.1%+7.8%1.1%
TVTXTravere Therapeutics, Inc.LTM Sep 2026$52.78M USD-3.5%+43.1%8.1%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$28.19M USD+36.7%+0.9%2.9%
INSMInsmed IncorporatedLTM Jun 2026$19.73M USD+59.7%+16.8%1.7%
ASNDAscendis Pharma A/SLTM Sep 2026€18.33M EUR+5.7%-1.8%1.5%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026$13.62M USD-61.8%+24.3%2.0%
PHARPharming Group N.V.LTM Mar 2026$8.54M USD-34.4%—2.3%
BBIOBridgeBio Pharma, Inc.LTM Jun 2026$5.07M USD-7.9%-7.1%0.7%
Peer median (excluding BMRN) —+1.3%+7.8%1.9%

Competitors are the stored peer set for BMRN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(64.08M)141.56M167.65M426.86M348.9M
Depreciation & Amortization108.04M101.97M104.39M96.43M79.56M
Deferred Income Tax(15.61M)(52.09M)(44.98M)56.1M48.74M
Stock-Based Compensation197.26M196.31M207.1M201.57M181.41M
Change in Working Capital66.03M(96.38M)(336.54M)(216.4M)(108.68M)
Accounts Receivables65.57M(82.03M)(190.44M)(57.91M)(228.05M)
Inventory(35.06M)(68.26M)(157.06M)(63.53M)119.21M
Accounts Payables15.69M59.02M68.85M(32.24M)66.14M
Other Working Capital19.83M(5.1M)(57.9M)(62.72M)(65.97M)
Other Non-Cash Items12.89M(115.47M)61.65M8.29M278.07M
Operating Cash Flow304.54M175.9M159.26M572.84M827.99M
Capital Expenditures(119.23M)(120.96M)(107.61M)(97.42M)(103.04M)
Acquisitions (Net)0000(285.19M)
Purchases of Investments(937.14M)(611.81M)(868.5M)(410.25M)(355.88M)
Sales of Investments691.05M620M864.86M633.02M337.8M
Other Investing Activities(24.64M)103.33M(10.92M)(853K)(7.94M)
Investing Cash Flow(366.31M)(20.03M)(111.24M)136.49M(414.24M)
Debt Repayment(3.04M)(2.61M)(2.29M)(494.99M)0
Common Stock Issued069.33M69.35M014.46M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities2.99M(85.38M)(85.79M)(31.46M)(56.85M)
Financing Cash Flow(48K)(18.65M)(18.73M)(526.45M)(42.39M)
Effect of Forex Changes(57K)32K1.31M4.83M(2.52M)
Net Change in Cash(61.88M)137.26M30.6M187.72M368.84M
Free Cash Flow185.31M54.94M51.65M475.42M724.96M

BioMarin Pharmaceutical Inc.

NASDAQ:BMRN

Intrinsic Alpha fair value

Locked

Current Price

$61.43

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.